Cipla announced price cut in three additional anti-cancer drugs Erlotinib (Erlocip) , Docetaxel (Docetax) and Capecitabine (Capegard) recently. Earlier, the company had announced price reduction on three major anti-cancer drugs - Sorafenib (Soranib), Gefitinib (Gefticip) and Temozolomide (Temoside) in May 2012.
These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head and
neck cancer, gastric cancer, bladder, colorectal and colon cancers.
"Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to now include cancer, not only in India but globally," said Y K Hamied, chairman and managing director, Cipla Limited.
As part of this commitment, in 1997, the company established the Cipla Palliative Care and Training Centre in Pune, to provide care to advanced stage cancer patients. The Centre provides free treatment and has cared for over 8,000 patients till date. It has also trained a large number of nurses in advanced palliative care.
.JPG)
Cipla laid the foundation for the Indian pharmaceutical industry in 1935. The company has over 34 manufacturing facilities across India, and manufactures over 2,000 products in 65 therapeutic categories. With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 170 countries.
Hey this blog is very nice Soranib
ReplyDelete